Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Prudential PLC

Prudential PLC decreased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,737 shares of the medical equipment provider’s stock after selling 2,283 shares during the period. Prudential PLC’s holdings in Lantheus were worth $1,229,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in Lantheus in the 4th quarter valued at about $323,000. Focus Financial Network Inc. purchased a new position in Lantheus during the 4th quarter valued at about $292,000. Finally, Harbor Capital Advisors Inc. raised its position in Lantheus by 12.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock worth $13,006,000 after acquiring an additional 16,466 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $95.45 on Tuesday. The firm has a market capitalization of $6.54 billion, a price-to-earnings ratio of 15.88 and a beta of 0.20. The company has a 50 day moving average price of $93.26 and a 200 day moving average price of $95.94. Lantheus Holdings, Inc. has a one year low of $58.46 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LNTH. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.